- CD
Crohn's disease
Crohn's disease: background
Crohn's disease (CD) and a related condition, ulcerative colitis, are collectively referred to as inflammatory bowel disease. CD is a lifelong chronic relapsing and remitting inflammatory condition of the gastrointestinal tract. Symptoms include diarrhoea, abdominal pain, fever and fatigue. The disease is named after Dr Burrill B Crohn, who in 1932, along with his colleagues, published a landmark paper describing ‘regional ileitis’, which is now known as CD(Reference Crohn, Ginzburg and Oppenheimer1).
The incidence of CD is estimated at 6·7 cases per 100 000 annually, with a prevalence of 140 cases per 100 000 in the Western world(Reference Loftus2). CD may be diagnosed at any age, including childhood, but typically presents in late adolescence and early adulthood (15–30 years of age). The disease therefore affects individuals during their most active years and is associated with increased morbidity, hospitalisation, surgery, medical and nutritional complications and high healthcare costs. For individuals with this condition it can be debilitating, resulting in poor quality of life, reduced daily functioning and the potential to cause lifelong ill health.
Given the symptoms and nature of this condition, nutritional issues are important. The present review sets out to address three key questions relating to nutrition in CD: (1) is diet a risk factor for the development of the disease; (2) what are the main nutrition-related issues in disease management; (3) are dietary approaches effective for treating active disease.
Is diet a risk factor for the development of Crohn's disease?
The exact aetiology of CD remains unknown. The consensus is that the disease results from a complex interaction between genes, immunity and environmental factors(Reference Hanauer3). There is a known genetic component to CD; the disease runs in families and 20–25% of patients have a first-degree relative with either CD or ulcerative colitis. More recent advances in genetics show that mutations in the NOD2/CADD15 gene, located on chromosome 16, are associated with increased susceptibility to the disease(Reference Ogura, Bonen and Inohara4, Reference Hugot, Chamaillard and Zouali5). Cigarette smoking is one of the best-described environmental risk factors(Reference Loftus2, Reference Birrenbach and Bocker6), with smokers twice as likely to develop CD as non-smokers. Several other risk factors have been proposed, including diet, socio-economic factors and childhood infections(Reference Loftus2).
Diet is attractive, in theory, as an environmental risk factor in the aetiology of the disease. Westernised diets, typically characterised by high fat, high sugar and low fibre intakes, have been proposed as a risk factor for the development of CD(Reference Mahmud and Weir7). The increasing incidence of the disease in countries such as Japan coincides with changes to more Westernised diets(Reference Shoda, Matsueda and Yamato8). A number of case–control studies conducted in the 1970s and 1980s have identified refined sugars as a potential risk factor(Reference Mayberry, Rhodes and Allan9, Reference Martini and Brandes10); however, this finding has yet to be confirmed by large prospective studies. A larger case–control study has implicated consumption of chocolate and cola drinks as possible risk factors for the disease(Reference Russel, Engels and Muris11). Overall, the data showing a relationship between sugar intake and onset of CD are inconsistent(Reference Riordan, Ruxton and Hunter12) and there is limited convincing evidence that high sugar intakes relate to disease onset. Similarly for fats, some studies have implicated monounsaturated and polyunsaturated fats in the development of the disease(Reference Shoda, Matsueda and Yamato8, Reference MacLean, Mojica and Newberry13). A hospital-based case–control study from Japan has shown that the consumption of sugars, sweeteners and confectionery as well as fats and oils (intakes of total fat, MUFA, PUFA and n-3 and n-6 fatty acids) are positively associated with CD risk(Reference Sakamoto, Kono and Wakai14). Overall, the putative role of fats and sugar in the development of the disease remains inconclusive.
More recently, a Canadian study has revisited this issue of diet as a risk factor(Reference Amre, D'Souza and Morgan15). In a case–control study the dietary habits were assessed 1 year before disease onset in 130 children with CD compared with 202 controls. The findings suggested that intakes of fruit and vegetables, fish and nuts were associated with a lower risk of developing the disease in children. Data for fat intake were also reported, showing a negative association between consumption of long-chain n-3 fatty acids and CD, with a higher long-chain n-3:n-6 fatty acids associated with lower risks for the disease(Reference Amre, D'Souza and Morgan15). These findings, however, need to be confirmed in larger rigorously-conducted prospective studies.
There are several methodological challenges in providing supporting evidence that diet is a truly causative agent in CD. In retrospective studies it may be difficult to determine whether dietary patterns have occurred because of the disease symptoms rather than contributing to the development of the disease, bearing in mind that the onset of the disease may precede the diagnosis by a considerable time. Several methodological issues, particularly in relation to recalled dietary intakes, have been highlighted(Reference Riordan, Ruxton and Hunter12). The relatively low incidence of the disease is also a challenge to studying the role of dietary factors in disease onset in large cohorts. Moreover, dietary habits may be markers for aspects of lifestyle other than diet, such as socio-economic factors, childhood factors, educational status and access to health care. For an individual with CD eating in general or eating specific foods may aggravate gastrointestinal symptoms without having a causative role in the disease.
In summary, to date, there is no conclusive evidence that pre-illness diet directly contributes to the pathogenesis of CD. There is currently no recommended diet-specific approach to reducing the risk of developing CD, over and above general healthy eating and lifestyle advice aimed at the general population. Once CD is diagnosed, however, nutrition does have an important role in the management of this chronic digestive condition.
What are the nutritional issues and challenges in CD?
There are many nutritional challenges in managing patients with CD throughout the course of their disease. These challenges include malnutrition in hospitalised patients, malabsorption, short bowel syndrome, micronutrient status(Reference Filippi, Al-Jaouni and Wiroth16, Reference Johtatsu, Andoh and Kurihara17), Fe-deficiency anaemia(Reference Gasche, Berstad and Befrits18) and osteoporosis(Reference Scott, Gaywood and Scott19, Reference Bernstein and Leslie20). For the purposes of the present review the focus is on the contrasting nutritional issues of malnutrition and overweight in CD and on the growing problem of vitamin D insufficiency.
Malnutrition in Crohn's disease
The causes of malnutrition in CD are multiple and include poor dietary intake, impaired nutrient digestion and absorption and increased nutrient requirements (Fig. 1). Malnutrition, weight loss and suboptimal nutritional status may be present at any stage of the disease but are often overt during acute illness and hospitalisation.
Fig. 1. Causes of malnutrition in Crohn's disease (CD).
A study of hospital admissions (n 502) has identified malnutrition in 40% of patients with inflammatory bowel disease(Reference Pirlich, Schutz and Kemps21); the highest prevalence of malnutrition among patients with benign diseases. Furthermore, patients with malnutrition spend 40% longer in hospital(Reference Pirlich, Schutz and Kemps21). Recently, a large study comprising >75 000 patients has highlighted a higher prevalence of protein–energy malnutrition among admissions for inflammatory bowel disease than admissions not for inflammatory bowel disease (6·1% compared with 1·8% respectively)(Reference Nguyen, Munsell and Harris22). The prevalence rates of malnutrition in this study are unusually low and are possibly underestimated because malnutrition was identified from information contained in national databases of hospital discharges rather than being measured specifically for the study. This approach is in contrast to hospital-based studies (for example, see Pirlich et al.(Reference Pirlich, Schutz and Kemps21)) in which malnutrition was measured by anthropometry and bioelectrical impedance. Nevertheless, it was found that when malnutrition is present patients have a higher mortality, longer hospital stays and higher healthcare costs(Reference Nguyen, Munsell and Harris22). In acutely-ill hospitalised patients malnutrition may be a marker of disease severity and poor prognosis. Hospitalised patients may often be malnourished on admission, which worsens while in hospital(Reference McWhirter and Pennington23). Thus, appropriate nutritional screening and intervention as part of the multidisciplinary management of CD is important.
While malnutrition during active disease or hospitalisation may be expected, the nutritional status of patients with inactive disease is less clear. Changes in lean body mass, muscle function and bone stores have been documented during remission(Reference Geerling, Badart-Smook and Stockbrugger24–Reference Valentini, Schaper and Buning26). Reduced hand-grip strength has been identified in patients with quiescent CD in the absence of other signs of malnutrition(Reference Nic Suibhne, O'Morain and O'Sullivan27). Also, reduced body cell mass and reduced hand-grip strength have been reported in CD in remission compared with controls(Reference Valentini, Schaper and Buning26). Reductions in muscle function and body cell mass have, therefore, been identified in patients considered well nourished according to routine measures such as BMI, serum albumin and screening tools such as the subjective global assessment and the malnutrition universal screening tool. It would appear, however, that the emerging findings in CD among outpatients and patients in clinical remission are an increase in BMI and the presence of overweight.
Overweight: the changing shape of Crohn's disease
CD is traditionally considered to be a disease associated with weight loss and low BMI. This perception, however, appears to be changing. In a study of children with newly-diagnosed CD most of the subjects (68%) were found to have a BMI in the normal range, with 10% classed as overweight or at risk for overweight(Reference Kugathasan, Nebel and Skelton28). Low BMI was documented in <25% of all children at diagnosis. These findings are illustrated in Fig. 2, which compares BMI data from two cohorts of American children with inflammatory bowel disease with data from normal healthy children(Reference Kugathasan, Nebel and Skelton28); they suggest that overweight or obesity should not preclude a diagnosis of CD in children(Reference Kugathasan, Nebel and Skelton28, Reference Sokol29). In adults the predominant form of malnutrition in patients in disease remission appears to be an excess of body fat(Reference Sousa Guerreiro, Cravo and Costa30). In a preliminary study the majority of patients, even those with signs of reduced muscle function, have been found to have a BMI that is normal or above normal, with 40% classed as overweight or obese(Reference Nic Suibhne, O'Morain and O'Sullivan27).
Fig. 2. Classification of BMI in 2748 US children in years 2001 and 2002, as determined by National Health and Nutrition Examination Surveys (NHANES) data (controls) and in children with newly-diagnosed Crohn's disease (CD) from the North American CD cohort (n 456) and the Wisconsin CD cohort (n 142). (
), BMI≥85th percentile (at risk of overweight or overweight); (□), BMI 5th–84th percentile (normal reference range); (▪), BMI<5th percentile (low). (Reproduced, with permission from Elsevier, from Kugathasan et al.(Reference Kugathasan, Nebel and Skelton28).)
Taken together, these findings suggest that individuals with CD, at least when in remission and not hospitalised, are similar to those for the general population and are influenced by the background population trends towards overweight and obesity. There are added concerns for this phenomenon in CD. Overweight may mask other aspects of poor nutritional status such as loss of lean body mass, bone loss or micronutrient deficiencies. It has been reported that macronutrient needs of patients in disease remission are met in ⩽70% of patients; micronutrient deficiencies, however, may be common and require specific screening(Reference Filippi, Al-Jaouni and Wiroth16). The consequences of overweight and excess body fat in the context of CD are not clear. It has been suggested that obese patients with CD are more prone to develop an active disease than matched non-obese patients with CD(Reference Blain, Cattan and Beaugerie31). Furthermore, obese patients with CD require surgery sooner than non-obese patients with CD(Reference Hass, Brensinger and Lewis32).
In the short term overweight among individuals with CD may reflect wellness and disease control. How overweight and excess adipose tissue interacts with a background of inflammation and contributes to relapse, comorbidity, long-term complications or disease course in CD remains to be seen. Adipose tissue, once considered to be an inert entity, is now known to produce several bioactive molecules including TNFα, which is a key pro-inflammatory cytokine in CD. Furthermore, a build up of intra-abdominal adipose tissue is a recognised feature of CD, which may contribute to intestinal inflammation(Reference Schaffler, Scholmerich and Buchler33).
Vitamin D insufficiency in Crohn's disease
Vitamin D deficiency is common in individuals with CD(Reference Siffledeen, Siminoski and Steinhart34, Reference Tajika, Matsuura and Nakamura35), with known implications for the risk of bone disease. Vitamin D stimulates bone matrix formation and maturation and promotes Ca absorption from the gut and kidney (for review, see Lanham-New(Reference Lanham-New36)). The relative risk of fractures is 40% greater in patients with inflammatory bowel disease than in the general population. The prevalence of osteopenia and osteoporosis is estimated at 50% and 15% respectively(Reference Bernstein, Leslie and Leboff37). Corticosteroid therapy, malabsorption, malnutrition, inflammation and hormonal and genetic factors as well as vitamin D and Ca status contribute to this increased risk of bone disease. As far back as 2000 the British Society of Gastroenterology highlighted the importance of recognising and treating vitamin D deficiency in individuals with CD and have recommended daily vitamin D supplements of 20 μg for patients taking systemic corticosteroids(Reference Scott, Gaywood and Scott19).
Individuals with CD are at most risk of vitamin D deficiency in winter(Reference McCarthy, Duggan and O'Brien38), especially in countries of northern latitudes, because the lack of sunlight during winter months results in poor stimulation of vitamin D production in the skin. Diet alone is unlikely to maintain adequate serum vitamin D status, as few foods, apart from oily fish and fortified foods, are good sources of this vitamin. Dietary vitamin D may be further compromised for individuals with CD by poor dietary intakes and malabsorption.
Defining optimal serum 25-hydroxyvitamin D level in Crohn's disease
Serum 25-hydroxyvitamin D is the biomarker most commonly used to assess vitamin D status. The most appropriate thresholds for determining vitamin D status are an issue of debate(Reference Lips39–Reference Vieth and Carter41). The focus of this argument is on determining the optimal level for health as opposed to the minimum level to prevent deficiency and severe bone disease such as osteomalacia and rickets. Broadly speaking, a level of 40 or 50 nmol/l(Reference Lips39, Reference Vieth and Carter41, Reference Hypponen and Power42) is used to define insufficient or inadequate vitamin D status. Other researchers propose higher cut-off levels of the order of 75–80 nmol/l(Reference Heaney40, Reference Hypponen and Power42). The debate about 25-hydroxyvitamin D is pertinent to CD because higher disease-specific levels may well be required to prevent bone disease in this at-risk group. Moreover, 25-hydroxyvitamin D levels that promote anti-inflammatory effects, if any, in CD have yet to be determined.
Vitamin D: possible anti-inflammatory role of vitamin D in Crohn's disease
There is growing evidence to suggest a role for vitamin D beyond its role in bone health in CD. Deficiency of vitamin D has been reported to accelerate the development of symptoms of inflammatory bowel disease in IL-10-knock-out mice(Reference Cantorna, Munsick and Bemiss43), while dietary vitamin D and Ca have been reported to suppress experimental colitis by inhibition of the TNFα pathway(Reference Zhu, Mahon, Froicu and Cantorna44). Recently, anti-inflammatory effects of vitamin D on T-cells derived from patients with CD have been described(Reference Bartels, Jorgensen and Agnholt45); in this study 1,25-dihydroxycholecalciferol was found to increase IL-10 and reduce interferon-γ production.
Vitamin D insufficiency in Crohn's disease: spectrum of a wider public health problem
The identification of vitamin D insufficiency is, of course, not isolated to CD. Indeed, numerous studies now suggest that hypovitaminosis D is widespread in adult normal populations(Reference Hypponen and Power42, Reference McCarthy, Collins and O'Brien46–Reference Chapuy, Preziosi and Maamer48). A large cohort study of British adults has documented hypovitaminosis D in 47% of participants in winter and spring and 15% during summer and autumn. Similarly, a high prevalence (51%) of vitamin D insufficiency has been reported among healthy Irish adults, with half (51%) classed as vitamin D insufficient, rising to 58% in winter(Reference O'Sullivan, Nic Suibhne and Cox49). Substantial work now shows that vitamin D deficiency is common in the general population, suggesting that the high prevalence of deficiency in CD is part of a spectrum of a wider public health issue. The deficiency, however, may be more common and more severe among individuals with CD and the consequences of poor vitamin D status are likely to be considerable in terms of the added risk of bone disease and the potential role in suppressing inflammation.
Is nutrition effective in the treatment of Crohn's disease?
Adults
In the early 1970s enteral nutrition, in the form of an elemental diet, was shown to have a primary therapeutic effect in CD(Reference Voitk, Echave and Feller50, Reference Fisher, Foster and Abel51). An elemental diet provides nutrients in their simplest form, i.e. protein as free amino acids, carbohydrate as glucose or short-chain maltodextrins and fat as short-chain TAG. Elemental diets were used initially to nourish patients before surgery and some of these patients with CD were found to inadvertently improve symptomatically, which suggested that the diet may have had a primary therapeutic effect(Reference Voitk, Echave and Feller50, Reference Fisher, Foster and Abel51). In the 1980s the first controlled trial confirmed that an elemental diet is as effective as corticosteroids in inducing clinical remission in active CD(Reference O'Morain, Segal and Levi52). Several subsequent studies have supported this therapeutic effect and have also shown that the less-expensive and more-palatable polymeric (whole-protein) enteral formulas are equally as effective as an elemental diet(Reference Sanderson, Udeen and Davies53–Reference Giaffer, North and Holdsworth55).
The therapeutic approach of enteral nutrition is based on administering the feed as the only source of nutrition either orally or by nasogastric tube for 1–2 weeks. The practicalities of this regimen for adult patients, who may have other therapeutic options, should be considered. Poor compliance typically results in poor outcome irrespective of the therapeutic agent; suggestions on overcoming the practical challenges for the use of enteral nutrition in adults with CD are detailed elsewhere(Reference O'Sullivan and O'Morain56–Reference Teahon, Pearson and Levi58).
More recent evaluation, based on meta-analyses(Reference Fernandez-Banares, Cabre and Esteve-Comas59, Reference Messori, Trallori and D'Albasio60) and a Cochrane review(Reference Zachos, Tondeur and Griffiths61), now show that corticosteroids are more effective than enteral nutrition therapy in adults. Current guidelines mirror this finding, recommending that enteral nutrition is less effective than corticosteroids in the treatment of active CD, but that it may be considered as therapy for adults in special circumstances, e.g. where other primary therapy may not be feasible(Reference Carter, Lobo and Travis62). As adjunctive therapy, nutritional support is recommended for any malnourished patient with CD or for patients with difficulty maintaining normal nutritional status (Table 1). The role of nutritional therapy in the management of adult CD in the future remains uncertain(Reference O'Sullivan and O'Morain57, Reference Gassull63, Reference Matsui, Sakurai and Yao64), particularly in the era of newer therapeutic approaches such as biologic therapy that have changed the management of this disease(Reference Rutgeerts, Van Assche and Vermeire65). Moreover, in adults guidelines recommend using enteral nutrition in special circumstances rather than as a generic therapy. Clearly, its role in managing malnourished patients or those at risk of malnutrition is undisputed (Table 1).
Table 1. Summary of guidelines for enteral nutrition as primary therapy in Crohn's disease
EN, enteral nutrition (oral nutritional supplements or tube feeding); CD, Crohn's disease; n/a, not applicable.
Children
In children with CD the rationale for using enteral nutrition as the primary therapy is stronger. In addition to the therapeutic effect(Reference Dziechciarz, Horvath and Shamir66), nutritional therapy has positive effects on growth and development(Reference Day, Whitten and Sidler67, Reference Newby, Sawczenko and Thomas68) and may reduce the use of corticosteroids(Reference Knight, El-Matary and Spray69). A recent meta-analysis has concluded that enteral nutrition has similar efficacy to corticosteroids in children, but has cautioned that this outcome is based on limited data(Reference Dziechciarz, Horvath and Shamir66). A Cochrane review of strategies for growth failure in children with CD has highlighted the positive effect of enteral nutrition therapy in promoting growth(Reference Newby, Sawczenko and Thomas68). In children enteral nutrition is recommended as first-line therapy for active disease, especially for those with growth failure (Table 1). As a maintenance therapy to prolong remission, enteral nutrition, in addition to normal diet, has been shown to prolong remission and improve linear growth in children who have achieved remission by exclusive enteral nutrition(Reference Wilschanski, Sherman and Pencharz70).
Mode of action
The mechanisms underlying the therapeutic response to enteral nutrition remain unclear. There is evidence that enteral nutrition therapy promotes mucosal healing and down regulates mucosal pro-inflammatory cytokines(Reference Fell, Paintin and Arnaud-Battandier71, Reference Yamamoto, Nakahigashi and Saniabadi72). Low antigenic load (absence of whole protein) was initially proposed to contribute to the therapeutic effect, but it is now known, however, that whole-protein enteral feeds are as effective as the amino acid-based elemental diets(Reference Verma, Brown and Kirkwood73). Other theories(Reference O'Sullivan and O'Morain74) relate to the provision of fatty acids(Reference Gassull, Fernandez-Banares and Cabre75), changes in gut flora and changes in intestinal permeability. Better understanding of the biological mechanisms underlying a therapeutic response, as well as the phenotypic and genotypic factors that predict this response, may allow more innovative approaches to diet therapy in the future.
In summary, enteral nutrition arguably offers a safe mode of delivery of potentially immune-modifying substrates directly to the gastrointestinal mucosa. Its role, however, as primary therapy for CD in adults remains uncertain in the light of pharmacological advances, such as biologic therapy, that have changed the management of this disease. Judged in the context of the best evidence and consensus guidelines, enteral nutrition is shown to be less effective than corticosteroids in adults but is an effective and important first-line therapy for children.
Conclusion
Diet is attractive, in theory, as an environmental risk factor in the aetiology of CD. Currently, there is no conclusive evidence, however, that pre-illness diet is a risk factor for development of this disease. How Westernised diets and environmental factors contribute to the pathogenesis of this disease remain active areas of research interest. Once CD is diagnosed, nutrition has an important role in disease management; in particular, the prevention and treatment of malnutrition is a key clinical priority throughout all stages of this disease. While individuals with CD have disease-specific nutritional needs, they appear to be influenced also by the wider-population health issues such as vitamin D deficiency and overweight. Vitamin D deficiency is common in CD and has important implications for bone health. While CD is traditionally associated with weight loss, the emerging picture suggests that overweight may be common, particularly in patients in clinical remission.
Acknowledgements
The author declares no conflict of interest. This work was supported by The Meath Foundation Dublin.
